Sikkim Journal

Key Players such as Eisai, EIP Pharma, and others are developing therapies to enhance treatment modalities in the Lewy Body Dementia market

 Breaking News
  • No posts were found

Key Players such as Eisai, EIP Pharma, and others are developing therapies to enhance treatment modalities in the Lewy Body Dementia market

December 24
16:04 2021
Key Players such as Eisai, EIP Pharma, and others are developing therapies to enhance treatment modalities in the Lewy Body Dementia market
Lewy Body Dementia Market
The Lewy Body Dementia market dynamics are expected to change in the coming years

DelveInsight’s Lewy Body Dementia market report thoroughly explains the Lewy Body Dementia historical and forecasted epidemiology and the Lewy Body Dementia market trends in the 7MM.

Some of the Key Highlights from the Lewy Body Dementia Market Report

  • According to a 2020 study titled “Lewy Body Dementia” by Haider et al., Lewy Body Dementia accounts for up to 20% to 30% of all dementia cases and is more common in men.
  • According to the study titled “Promoting independence in Lewy body dementia through exercise (PRIDE) study: Protocol for a pilot study” by Inskip et al. (2019), LBD has a variable estimated prevalence of up to 24% of all dementia diagnoses.
  • Leading companies in the Lewy Body Dementia market include Eisai, EIP Pharma, Sun Pharma, and others.
  • Key Lewy Body Dementia therapies in the pipeline include E2027, Neflamapimod, K0706, and others. 

Request for a sample to know more @ Lewy Body Dementia Market Analysis

Lewy Body Dementia: Overview

Lewy Body Dementia (LBD) is a neurological disorder characterized by abnormal deposits of the protein alpha-synuclein in the brain. These deposits, known as Lewy bodies, affect chemicals in the brain, causing changes that can lead to problems with thinking, movement, behavior, and mood. One of the most common causes of dementia is Lewy body dementia.

Lewy Body Dementia Epidemiology Segmentation

The Lewy Body Dementia report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

  • Lewy Body Dementia Prevalent Population
  • Lewy Body Dementia Gender-Specific Prevalent Population
  • Lewy Body Dementia Diagnosed and Treatable Cases

Lewy Body Dementia Treatment Landscape

Numerous Lewy Body Dementia treatments are available to help with the symptoms; the Food and Drug Administration has approved all medications prescribed for LBD to treat symptoms in other diseases, such as Alzheimer’s and Parkinson’s. These medications may provide symptomatic relief for cognitive, movement, sleep, mood, and behavioral changes associated with LBD. There are currently no medications available to slow or stop the progression of LBD. Cholinesterase inhibitors such as rivastigmine (Exelon), donepezil (Aricept), and galantamine (Razadyne) are the gold standard for treating cognitive symptoms in LBD.

Lewy Body Dementia Market Outlook

The Lewy Body Dementia market dynamics are expected to change in the coming years as research and development activities improve, resulting in a market with efficient LBD treatment options.

Get a detailed analysis of the market @ Lewy Body Dementia Market Outlook

Lewy Body Dementia Pipeline Therapies and Key Companies

  • E2027: Eisai
  • Neflamapimod: EIP Pharma
  • K0706: Sun Pharma

Table of Contents

1.

Report Introduction

2.

Lewy Body Dementia (LBD): Market Overview at a Glance

3.

Disease Background and Overview: Lewy Body Dementia (LBD)

4.

Epidemiology and Patient Population (7MM)

5.

Lewy Body Dementia (LBD): Country-wise Epidemiology

6.

Treatments & Medical Practices

7.

Current Treatment

8.

Emerging Therapies

9.

Lewy Body Dementia (LBD): Market Size 

10.

7MM: Country-wise Market Analysis

11.

Market Drivers

12.

Market Barriers

13.

KOL views

14.

Market Access and reimbursement

15.

Patient Journey

16.

Report Methodology

17.

DelveInsight Capabilities

18.

Disclaimer

19.

About DelveInsight

Get in touch with our business executive for Healthcare Due Diligence Services

Related Reports

Dementia with Diabetes Market

DelveInsight’s ‘Dementia with Diabetes—Market Insights, Epidemiology and Market Forecast–2030’ report delivers an in-depth understanding of the Dementia with Diabetes, historical and forecasted epidemiology as well as the Dementia with Diabetes market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/